In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Pfizer on Wednesday said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run ...

In that case, Pfizer could make as much as $5.8 billion in a year from Paxlovid. That's roughly in line with the $5.3 billion cost of the supply that the government initially purchased.

Topline Pfizer said on Monday it will spend $120 million to boost production of its Covid-19 antiviral treatment Paxlovid, as the White House continues its efforts to increase access to the first ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE stock remains undervalued at its ...

Doses of the anti-viral drug Paxlovid are displayed in New York, on Monday, Aug. 1, 2022. Pfizer's COVID-19 pill may provide little benefit for younger adults, while still reducing the risk of ...

In a study designed to test Paxlovid in "standard-risk" adults, Pfizer enrolled more than 1,100 people ages 18 and up. To join the study, they had to be within five days of a positive Covid-19 ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...